Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier

被引:648
作者
Kreuter, J
Shamenkov, D
Petrov, V
Ramge, P
Cychutek, K
Koch-Brandt, C
Alyautdin, R
机构
[1] Goethe Univ Frankfurt, Inst Pharmazeut Technol, Biozentrum, D-60439 Frankfurt, Germany
[2] Moscow Med Acad, Dept Pharmacol, Moscow, Russia
[3] Paul Ehrlich Inst, Dept Med Biotechnol, D-6070 Langen, Germany
[4] Johannes Gutenberg Univ Mainz, Inst Biochem, D-6500 Mainz, Germany
关键词
apolipoprotein B; apolipoprotein E; nanoparticles; blood-brain barrier; drug delivery to the brain; dalargin; loperamide;
D O I
10.1080/10611860290031877
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies have shown that drugs that are normally unable to cross the blood-brain barrier (BBB) following intravenous injection can be transported across this barrier by binding to poly(butyl cyanoacrylate) nanoparticles and coating with polysorbate 80. However, the mechanism of this transport so far was not known. In the present paper, the possible involvement of apolipoproteins in the transport of nanoparticle-bound drugs into the brain is investigated. Poly(butyl cyanoacrylate) nanoparticles loaded with the hexapeptide dalargin were coated with the apolipoproteins All. B, CII E, or J without or after precoating with polysorbate 80. In addition, loperamide-loaded nanoparticles were coated with apolipoprotein E alone or again after precoating with polysorbate 80. After intravenous injection to ICR mice the antinociceptive threshold was measured by the tail flick test. Furthermore, the antinociceptive threshold of polysorbate 80-coated dalargin-loaded nanoparticles was determined in ApoEtmIUnc and C57BL/6J mice. The results show that only dalargin or loperamide-loaded nanoparticles coated with polysorbate 80 and/or with apolipoprotein B or E were able to achieve an antinociceptive effect. This effect was significantly higher after polysorbate-precoating and apolipoprotein B or E-overcoating. With the apolipoprotein E-deficient ApoEtmIUnc mice the antinociceptive effect was considerably reduced in comparison to the C57BL/6J mice. These results suggest that apolipoproteins B and E are involved in the mediation of the transport of drugs bound to poly(butyl cyanoacrylate) nanoparticles across the BBB. Polysorbate 80-coated nanoparticles adsorb these apolipoproteins from the blood after injection and thus seem to mimic lipoprotein particles that could be taken up by the brain capillary endothelial cells via receptor-mediated endocytosis. Bound drugs then may be further transported into the brain by diffusion following release within the endothelial cells or, alternatively, by transcytosis.
引用
收藏
页码:317 / 325
页数:9
相关论文
共 38 条
[1]  
ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
[2]   Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J].
Alyautdin, RN ;
Petrov, VE ;
Langer, K ;
Berthold, A ;
Kharkevich, DA ;
Kreuter, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (03) :325-328
[3]   Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study [J].
Alyautdin, RN ;
Tezikov, EB ;
Ramge, P ;
Kharkevich, DA ;
Begley, DJ ;
Kreuter, J .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (01) :67-74
[5]  
Brightman M, 1992, HDB EXPT PHARM, V103, P1
[6]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[7]  
Davson H, 1996, PHYSL CSF BLOOD BRAI, P1
[8]   A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier [J].
Dehouck, B ;
Fenart, L ;
Dehouck, MP ;
Pierce, A ;
Torpier, G ;
Cecchelli, R .
JOURNAL OF CELL BIOLOGY, 1997, 138 (04) :877-889
[9]   UP-REGULATION OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR AT THE BLOOD-BRAIN-BARRIER - INTERCOMMUNICATIONS BETWEEN BRAIN CAPILLARY ENDOTHELIAL-CELLS AND ASTROCYTES [J].
DEHOUCK, B ;
DEHOUCK, MP ;
FRUCHART, JC ;
CECCHELLI, R .
JOURNAL OF CELL BIOLOGY, 1994, 126 (02) :465-473
[10]  
Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017